New Haven, CT, March 8, 2016 – New Haven Pharmaceuticals, Inc. today announced the results of a Company sponsored survey that showed patients with a history of one or more cardiovascular events and were taking a daily dose of aspirin, had generally more favorable attitudes toward the use of prescription compared with OTC medications. This is the first and only survey, conducted in a Harris Poll of 1,000 people, to access attitudes and beliefs regarding the use of prescription and OTC medications in patients taking aspirin for the prevention of secondary cardiac events. The survey results also showed that most respondents believed that aspirin was a beneficial part of their cardiovascular prevention regimen, and they were not averse to participating in active prescription management regimes for aspirin, which could enhance overall patient adherence to treatment.
You are here
New Haven, CT, February 29, 2016 – New Haven Pharmaceuticals, Inc. today announced positive study data that shows that DURLAZA ™ is well tolerated, with a favorable safety profile comparable to immediate release low dose aspirin and delivers sustained antiplatelet control for a full 24-hour period in high-risk cardiovascular and diabetes patients. These data were highlighted during poster presentations at the Annual American College of Preventive Medicine (ACPM) meeting in Arlington, VA.
New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZATM, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. DURLAZA is now commercially available for physicians and their patients.